Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Portfolio Pulse from Charles Gross
Moderna, Inc. (MRNA) and Immatics N.V. (IMTX) have announced a strategic research and development collaboration to develop innovative oncology therapeutics. The collaboration will combine Immatics’ TCR platform with Moderna’s mRNA technology, and span various therapeutic modalities including bispecifics, cell therapy and cancer vaccines. The collaboration will focus on three main areas: mRNA technology for in vivo expression of Immatics’ TCR bispecifics, discovery and development of novel mRNA-based cancer vaccines, and evaluating Immatics’ IMA203 TCR-T therapy targeting PRAME in combination with Moderna’s PRAME mRNA-based cancer vaccine.
September 11, 2023 | 10:40 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immatics' collaboration with Moderna to develop innovative oncology therapeutics could potentially enhance its product pipeline and market position in the oncology sector.
The collaboration with Moderna could potentially lead to the development of innovative oncology therapeutics, which could enhance Immatics' product pipeline and strengthen its market position in the oncology sector. This could potentially have a positive impact on Immatics' stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Moderna's collaboration with Immatics to develop innovative oncology therapeutics could potentially boost its portfolio and market position in the oncology sector.
The collaboration with Immatics could potentially lead to the development of innovative oncology therapeutics, which could boost Moderna's portfolio and strengthen its market position in the oncology sector. This could potentially have a positive impact on Moderna's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100